167 related articles for article (PubMed ID: 38137355)
1. Expression of Claudin-9 (CLDN9) in Breast Cancer, the Clinical Significance in Connection with Its Subcoat Anchorage Proteins ZO-1 and ZO-3 and Impact on Drug Resistance.
Zhuang X; Martin TA; Ruge F; Zeng JJ; Li XA; Khan E; Dou Q; Davies E; Jiang WG
Biomedicines; 2023 Nov; 11(12):. PubMed ID: 38137355
[TBL] [Abstract][Full Text] [Related]
2. Claudin‑9 is a novel prognostic biomarker for endometrial cancer.
Endo Y; Sugimoto K; Kobayashi M; Kobayashi Y; Kojima M; Furukawa S; Soeda S; Watanabe T; Higashi AY; Higashi T; Hashimoto Y; Fujimori K; Chiba H
Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36129146
[TBL] [Abstract][Full Text] [Related]
3. Zonula occludens-1 and Her-2/neu expression in invasive breast carcinoma.
Bell J; Walsh S; Nusrat A; Cohen C
Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):125-9. PubMed ID: 12777995
[TBL] [Abstract][Full Text] [Related]
4. Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.
Logullo AF; Pasini FS; Nonogaki S; Rocha RM; Soares FA; Brentani MM
Mol Clin Oncol; 2018 Oct; 9(4):377-388. PubMed ID: 30214726
[TBL] [Abstract][Full Text] [Related]
5. Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer.
Martin TA; Watkins G; Mansel RE; Jiang WG
Eur J Cancer; 2004 Dec; 40(18):2717-25. PubMed ID: 15571953
[TBL] [Abstract][Full Text] [Related]
6. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract][Full Text] [Related]
7. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
8. Disruption of ZO-1/claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis.
Hamada K; Kakigawa N; Sekine S; Shitara Y; Horie T
Cancer Chemother Pharmacol; 2013 Oct; 72(4):757-65. PubMed ID: 23963446
[TBL] [Abstract][Full Text] [Related]
9. The human urothelial tight junction: claudin 3 and the ZO-1α
Smith NJ; Hinley J; Varley CL; Eardley I; Trejdosiewicz LK; Southgate J
Bladder (San Franc); 2015; 2(1):e9. PubMed ID: 26269793
[TBL] [Abstract][Full Text] [Related]
10. The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients.
Zhu YY; Si W; Ji TF; Guo XQ; Hu Y; Yang JL
Tumour Biol; 2016 Jun; 37(6):7675-84. PubMed ID: 26687919
[TBL] [Abstract][Full Text] [Related]
11. Corneal epithelial tight junctions and their response to lipopolysaccharide challenge.
Yi X; Wang Y; Yu FS
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4093-100. PubMed ID: 11095601
[TBL] [Abstract][Full Text] [Related]
12. Variants of human CLDN9 cause mild to profound hearing loss.
Ramzan M; Philippe C; Belyantseva IA; Nakano Y; Fenollar-Ferrer C; Tona R; Yousaf R; Basheer R; Imtiaz A; Faridi R; Munir Z; Idrees H; Salman M; Nambot S; Vitobello A; Kartti S; Zarrik O; Witmer PD; Sobreria N; Ibrahimi A; Banfi B; Moutton S; Friedman TB; Naz S
Hum Mutat; 2021 Oct; 42(10):1321-1335. PubMed ID: 34265170
[TBL] [Abstract][Full Text] [Related]
13. Albumin impairs renal tubular tight junctions via targeting the NLRP3 inflammasome.
Zhuang Y; Hu C; Ding G; Zhang Y; Huang S; Jia Z; Zhang A
Am J Physiol Renal Physiol; 2015 May; 308(9):F1012-9. PubMed ID: 25715986
[TBL] [Abstract][Full Text] [Related]
14. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
15. Inducible expression of claudin-1-myc but not occludin-VSV-G results in aberrant tight junction strand formation in MDCK cells.
McCarthy KM; Francis SA; McCormack JM; Lai J; Rogers RA; Skare IB; Lynch RD; Schneeberger EE
J Cell Sci; 2000 Oct; 113 Pt 19():3387-98. PubMed ID: 10984430
[TBL] [Abstract][Full Text] [Related]
16. Biophysical characterization of interactions between the C-termini of peripheral nerve claudins and the PDZ₁ domain of zonula occludens.
Wu J; Peng D; Zhang Y; Lu Z; Voehler M; Sanders CR; Li J
Biochem Biophys Res Commun; 2015 Mar; 459(1):87-93. PubMed ID: 25712527
[TBL] [Abstract][Full Text] [Related]
17. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study.
Resnick MB; Konkin T; Routhier J; Sabo E; Pricolo VE
Mod Pathol; 2005 Apr; 18(4):511-8. PubMed ID: 15475928
[TBL] [Abstract][Full Text] [Related]
18. Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins.
Itoh M; Furuse M; Morita K; Kubota K; Saitou M; Tsukita S
J Cell Biol; 1999 Dec; 147(6):1351-63. PubMed ID: 10601346
[TBL] [Abstract][Full Text] [Related]
19. Tim-3 promotes cell aggressiveness and paclitaxel resistance through NF-κB/STAT3 signalling pathway in breast cancer cells.
Cong Y; Cui Y; Zhu S; Cao J; Zou H; Martin TA; Qiao G; Jiang W; Yu Z
Chin J Cancer Res; 2020 Oct; 32(5):564-579. PubMed ID: 33223752
[TBL] [Abstract][Full Text] [Related]
20. Roles of MALAT1 in development and migration of triple negative and Her-2 positive breast cancer.
Xiping Z; Bo C; Shifeng Y; Feijiang Y; Hongjian Y; Qihui C; Binbin T
Oncotarget; 2018 Jan; 9(2):2255-2267. PubMed ID: 29416769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
